CE vs PMCB · rev $10.28B vs $8.6M cap
Celanese Corporation (CE) versus PharmaCyte Biotech Inc (PMCB) — a side-by-side from cached financials, not a winner call.
Celanese Corporation (CE) is a chemicals company listed on US.
PharmaCyte Biotech Inc (PMCB) is a biotechnology company listed on NASDAQ.
Latest reported CE revenue for 2024-12-31 was $10.28B. Net income was -$1.51B. Revenue was down 6.0% from 2023-12-31 to 2024-12-31. CE currently screens at market cap $5.92B.
Latest reported PMCB revenue for 2025-04-30 was $0. Net income was $30.7M. PMCB currently screens at market cap $8.6M.
CE currently screens at market cap $5.92B. PMCB currently screens at market cap $8.6M.
Not investment advice. Open the CE and PMCB stock pages for the full models.
Not investment advice.